Compare Campbell Soup Co. (CPB) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Gilead Sciences, Inc. — how do they compare? Campbell Soup Co. trades at $19.15 (market cap $5.78B), while Gilead Sciences, Inc. trades at $148.68 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 31.6× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays the higher dividend (5.16%). Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and Gilead Sciences, Inc. for 111 Days on average.
| CPB | GILD | |
|---|---|---|
Market Cap | $5.78B | $182.40B |
Volume | 11,705,427 | 4,469,821 |
Sector | Consumer Staples | Health |
52-Week High | $31.66 | $155.80 |
52-Week Low | $18.90 | $116.74 |
Typical Hold Time | 98 Days | 111 Days |
Enterprise Value | $12.83B | $205.46B |
Dividend Yield | 5.16% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's stock trades at $18.90, down 0.53% with bearish technical signals. The company reported mixed Q2 2026 earnings, beating expectations but showing margin pressure. Recent dividend cut of 36% and workforce reduction signal turnaround efforts amid declining profitability. Valuation appears reasonable with P/E of 14.79 and P/S of 0.6, but revenue growth remains challenged.
The outlook remains cautious with analyst consensus leaning heavily toward Hold (58.62%). While cost-saving initiatives and balance sheet improvements provide some support, persistent margin compression and competitive pressures create headwinds. The stock trades near the lower end of analyst targets ($18-22), offering limited upside potential amid ongoing operational challenges.
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
